Does Wegovy Cause Gallbladder Issues Like Gallstones?
Yes, Wegovy (semaglutide) carries a risk of gallbladder-related problems, including gallstones (cholelithiasis), cholecystitis, and acute gallbladder disease. The prescribing information lists cholelithiasis as a common adverse reaction occurring in 1.6% of patients on the 2.4 mg weekly dose in clinical trials, compared to 0.7% on placebo. Gallbladder-related disorders overall affected 2.8% of Wegovy users versus 1.3% on placebo.[1][2]
This risk stems from rapid weight loss induced by GLP-1 receptor agonists like semaglutide, which increases bile cholesterol saturation and promotes stone formation. The FDA label warns of heightened risk during dose escalation or with faster weight loss.[1]
How Common Are These Issues in Studies?
In the STEP trials supporting Wegovy's approval:
- Gallbladder disorders: 2.5-4.5% of Wegovy patients vs. 1-2% placebo.
- Cholelithiasis specifically: Up to 1.9% on Wegovy.
Post-marketing reports include cases requiring cholecystectomy (gallbladder removal).[1][3]
Real-world data from a 2023 study in JAMA found semaglutide users had a 1.29-1.55 times higher adjusted risk of gallstones or cholecystitis compared to non-users, especially women and those with obesity.[4]
What Symptoms Should You Watch For?
Patients report abdominal pain (upper right side), nausea, vomiting, fever, or jaundice. These may signal gallstones or inflammation. Seek immediate care if symptoms appear, as delays can lead to complications like bile duct blockage.[1][2]
Who Is at Higher Risk?
- Rapid weight loss (>1-2 lbs/week).
- Women (2-3x higher baseline gallstone risk).
- History of gallstones or prior gallbladder surgery.
- Longer Wegovy use or higher doses.[3][4]
What Do Doctors Recommend?
Monitor with ultrasounds if symptoms arise. Lifestyle measures like gradual weight loss and hydration may help, but no preventive drug is proven. Discontinue if severe issues occur; risk often resolves post-weight stabilization.[1][2]
How Does This Compare to Ozempic or Other GLP-1 Drugs?
Same active ingredient as Ozempic (lower dose for diabetes), so identical gallbladder warnings. Similar risks with Mounjaro (tirzepatide): 0.6-1.7% cholelithiasis in trials. All carry boxed warnings for thyroid tumors, but gallbladder effects are class-wide due to weight loss mechanism.[1][5]
Sources
[1]: Wegovy Prescribing Information (FDA)
[2]: Novo Nordisk Wegovy Safety Info
[3]: NEJM STEP 1 Trial
[4]: JAMA Network Open (2023 Study)
[5]: Mounjaro Prescribing Information (FDA)